



A next generation precision  
oncology company


## OncoHost revolutionizes cancer care by mapping patient-tumor dynamics using proteomics and AI

First of its kind, comprehensive, truly personalized, and actionable navigator for cancer management across the continuum of the disease

OncoHost Ltd. is pursuing a well-defined and realistic business model with the goal of creating an early and substantial value for its shareholders and investors. The company will seek to establish itself as one of the leading cancer management companies.

Our first product the PROphet® – is a first of its kind test for supporting clinical decision-making in cancer management. PROphet® accurately predicts whether a cancer patient will respond to immunotherapy, outperforming currently available predictive tests. In addition, it identifies potential strategies to overcome resistance to treatment. The first release will be for non-small cell lung cancer (NSCLC) patients receiving checkpoint inhibitor immunotherapy targeting the PD-1/PD-L1 axis.

PROphet® is made possible through OncoHost's machine-learning and bioinformatics-based platform that translates blood proteomic profiles into clinically meaningful information. It is designed to detect tumor-therapy-host interactions in real-time – a breakthrough approach that will help physicians make informed clinical decisions to maximise clinical benefit for their patients. The test will also save costs by shortening duration of ineffective costly treatments and avoiding unnecessary toxicities.



1

### BROAD UTILITY

\$6B Initial target market out of \$21B TAM Applicable across high value indications

2

### SCALABLE

Clear path to the market, proven business model. No FDA approval required

3

### ACCURATE

Published results demonstrate accuracy of over 90% for response prediction

### Customers & Stakeholders



Empower every patient



Every Oncologist can be a 'precision medicine specialist'



Maximize outcomes & optimize costs for Every Payer



BioPharma services

In the first half of 2021 our major focus was **product**. We continue to improve the system's accuracy, our value proposition to our customers and stakeholders and the regulatory requirements to enter our first market in the US. In parallel, we concluded a successful ,oversubscribed funding round of \$7.5M and launching several important clinical collaborations.

#### **Product:**

The team is working diligently to release our MVP; the PROphet platform, the logistic operations (sample acquisition and handling), CRM system (salesforce) and of course our US based OncoHost CLIA lab. In addition, we are implementing a quality management system (QMS) with a planned ISO certification later this year. We devised our reimbursement strategy (following commercial launch) with Latham&Watkins a leading law firm specializing in reimbursement. Finally, we are concluding an early technology review process (ETR) a pre-launch stress test of our product, offering and value proposition with our actual customers. In this process we presented and discussed aspects of supporting scientific evidence, clinical value add and reimbursement potential with a tough (!) panel of key opinion oncology leaders and payors executives from the US, Canada and EU.

#### **R&D:**

We continuously improve our platform's accuracy by adding more patients to our analysis. Our latest analysis on a cohort of 110 lung cancer patients (non small cell lung cancer –NSCLC) yielded strong results with an additional improvement in system's accuracy and for the first time a unique map of cancer resistance. This map opens very interesting opportunities for OncoHost in terms of additional IP and pipeline products. New patent application is in process.

What's next?

- Finalize the MVP in preparation for commercial launch
- Add more indications– we are now assessing several opportunities for collaboration on more indications “PROphet baseline”– a next generation evolution of our platform that will require only one blood test
- “PROphet monitor” – a next generation product that will allow on going monitoring of patients in order to identify, as early as possible, disease relapse.

#### **Team:**

We hired a new head of product:

Ms. Ayelet Ran, an experienced product manager that is leading our product design effort.

We have 2 new board members–

Ms. Hila Karah, qualified board member with extensive professional investment experience. Hila is presently director at:

- Cyren Ltd. (**CYRN**, NASDAQ) since 2008 (member of the Compensation and Nomination committees)
- Intec Pharma Ltd. (**NTEC**, NASDAQ) since 2009 (member of the Audit and Compensation committees)
- DarioHealth Corp. (**DRIO**, NASDAQ) since 2014 (member of the Compensation committee)
- MyHeritage Ltd. (Private, observer) since 2006
- TillaCare. (Private) since 2017

Mr. Shlomo Schneider, an industrialist, entrepreneur, and an investor. Shlomo is also the chairman of the Ruth Vrabel foundation.

#### **IP:**

OncoHost currently has a strong IP position with 7 patent families and 48 applications. Good news “out of the oven” we have an official allowance for our IL 1 patent.

## Science:

To date our platform was developed on over 1400 samples and validated several hundreds. Clinical results were published in the leading scientific meetings in 2020-2021 including ASCO, AACR, ESMO, ESMO-MAP, CITC and EACR

2020



2021 YTD



## Collaborations:

Collaborating with more than 30 clinical trial sites in US, UK, EU, and Israel. We recently opened 8 clinical sites in collaboration with the NHS in the UK (<https://www.selectscience.net/industry-news/oncohost/nhs-opens-eight-uk-clinical-trial-sites-to-assess-cancer-patient-response-to-immunotherapy-in-collaboration-with-oncohost/?artID=54935>). More clinical sites will join our clinical trial this year. Several collaborations with leading clinical and research groups in US and EU- formal press releases will be made public later this year.

## Public relations and communications:

We have an ongoing communications program please follow up on LinkedIn <https://www.linkedin.com/company/oncohost>, and Twitter <https://twitter.com/OncoHost>. Please visit our website <https://oncohost.com/in-the-news/>.

YouTube: click on the photos



## Summary:

We are working hard and with pride to bring our first product to the market. The team is committed and engaged, our clinical investigators in the different sites acknowledge the need and recruit patients to our trial and we make good progress on all fronts.

We are building the next generation of precision oncology and the challenges are many. Nevertheless, we try not to forget why we are here. Patients are continuously approaching us via our website. I'd like to share with you a mail we received this week from a patient's (personal details were deleted of course):

"I have come across your technology whilst doing research to find another suitable trial and feel that this is something that could be invaluable to me as my cancer is so advanced i have little time to waste on treatment/ trials that will be of no benefit to me."

JW, a cancer patient (received from our website)

I'd like to thank you again for your support and belief in our journey. On behalf of myself and the team, we are committed to continuing our hard work towards bringing PROphet to the market.

Sincerely,

Ofer